Wukai Ma guided the treatment of the patient. == Discord OF INTEREST STATEMENT == The authors declare no conflict of interest. == ETHICS STATEMENT == Informed patient consent was obtained for the publication of any potentially identifiable images or data contained herein.Throughout the clinical course, patients were fully informed about the treatment and potential side effects and agreed to the treatment. == ACKNOWLEDGMENTS == The authors thank the patient and her family.The authors disclosed receipt of the following financial support for the publication of this article: Guizhou Provincial Clinical Research Center for Rheumatism and Immunology (Qian Kehe Platform Talent [2020] No. reversed. == Results and Conclusion == There is currently no statement of tofacitinib product therapy for antiMDA5 positive to unfavorable DM. With this case report, tofacitinib is an option for the treatment of antiMDA5positive DMILD, which deserves attention. Keywords:AntiMDA5 antibody, dermatomyositis, interstitial lung Ca2+ channel agonist 1 disease, JAK inhibitor, tofacitinib We have observed for the first time that tofacitinib is used in the treatment of demetomyositis with unfavorable anti MDA5 antibodies. == 1. INTRODUCTION == Dermatomyositis (DM) is an autoimmune disease with clinical manifestations of muscle mass and skin damage, often accompanied by multisystem involvement, especially in the lungs.1Positive antiMDA5 antibodies are highly associated with interstitial lung disease (ILD), which is one of the major mortality factors in DM patients.2Current conventional drug treatment for DMILD includes glucocorticoids, immunosuppressants, and antipulmonary fibrosis drugs.3Longterm use of glucocorticoids can lead to many adverse reactions, a high risk of immunosuppressive infections, unpredictable adverse drug reactions, and the duration of treatment with antipulmonary fibrosis drugs is not easy to manage, resulting in DMILD patients, especially those with positive antiMDA5 antibodies. The effective treatment rate is low. As a smallmolecule targeted drug, many studies have confirmed the effectiveness of tofacitinib in the treatment of patients with antiMDA5positive DMILD.4,5However, there is no report of the unfavorable conversion of antiMDA5 antibodies by tofacitinib treatment. Here we reported a case of antiMDA5 antibodypositive DMILD patients who were treated with hormones and immunosuppressive brokers in combination with tofacitinib Ca2+ channel agonist 1 and experienced unfavorable antiMDA5 antibodies, which is summarized below for clinical research. == 2. CASE Statement == A 51yearold female patient with a 10year history of psoriatic arthritis developed a paroxysmal cough and cough with white, sticky sputum after a chilly 5 months ago, accompanied by chills, general malaise, chest tightness, Ca2+ channel agonist 1 shortness of breath, back pain and hoarseness after exercise. She did not get any better after considering chilly treatment. 2 months later, feeling shortness of breath after activity and speech was worse than before, and there was scattered erythema around the neck, some of which merged into a piece, rough skin around the radial side of the right index finger, the distal end of the hands, and white skin after chilly, a chest CT was performed at an external hospital. Interstitial contamination in the right lobe, the lingual segment of the upper lobe of the left lung, and the lower lobes of both lungs were seen, and electronic bronchoscopy showed no abnormalities. Pulmonary function assessments showed moderate restrictive ventilatory dysfunction, small airway dysfunction, and moderate diffusion impairment. The electromyography showed a pattern of myogenic injury in the proximal muscle tissue of the extremities. Bilateral interstitial pneumonia and connective tissue disease were considered. To combat the infection, methylprednisolone 40 mg once daily and pirfenidone 200 mg three times daily was used for treatment, and the cough and sputum improved, with no improvement in shortness of breath after exercise, without further deterioration. After 4 months of activity, chest tightness, shortness of breath, cough and white sputum appeared. She went to the Department of Respiratory Medicine, West China Hospital, Sichuan University or college for examination of antiMi2 antibody, antiMDA5 antibody and antiPM Scl antibody (+). CT scan of the chest revealed vitreous opacities, patchy shadows, and gridlike shadows in both lung membranes, mostly due to interstitial inflammation in both lungs. Biopsy of the left deltoid muscle mass DM skeletal myopathy could not be excluded, followed by methylprednisolone modulation of immunity and no significant relief of symptoms after antiinfection. We considered our department to check the positive antiMDA5 antibody to diagnose DM, and to check the finger pulse. Oxygen 89% (no oxygen inhalation), dry and wet rales could be heard, a small amount scattered in the lower lungs, veclro rales could be heard in the bases of Rabbit polyclonal to CD10 both lungs, chest CT showed chronic interstitial changes in both lungs; mixed type in the lower lobes of both lungs (Determine1). Possibility of infection, fungus, procalcitonin, Creactive protein, erythrocyte sedimentation rate, muscle enzyme spectrum, electrolytes, thyroid function, tumor markers were normal, excluding other autoimmune diseases and tumors, sputum culture was Lewy prolonged bacillus infection, antibiotic antiinfective treatment and methylprednisolone 40.